1. Home
  2. EDRY vs XLO Comparison

EDRY vs XLO Comparison

Compare EDRY & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo EuroDry Ltd.

EDRY

EuroDry Ltd.

HOLD

Current Price

$23.55

Market Cap

55.6M

ML Signal

HOLD

XLO

Xilio Therapeutics Inc.

HOLD

Current Price

$8.37

Market Cap

49.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EDRY
XLO
Founded
2018
2016
Country
Greece
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
55.6M
49.8M
IPO Year
2018
2021

Fundamental Metrics

Financial Performance
Metric
EDRY
XLO
Price
$23.55
$8.37
Analyst Decision
Buy
Analyst Count
0
1
Target Price
N/A
$28.00
AVG Volume (30 Days)
20.5K
32.1K
Earning Date
06-04-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$43,766,000.00
Revenue This Year
$28.30
N/A
Revenue Next Year
$10.13
$168.77
P/E Ratio
N/A
N/A
Revenue Growth
N/A
589.88
52 Week Low
$7.64
$0.46
52 Week High
$24.00
$9.25

Technical Indicators

Market Signals
Indicator
EDRY
XLO
Relative Strength Index (RSI) 64.02 53.90
Support Level $11.73 $0.62
Resistance Level N/A $9.03
Average True Range (ATR) 1.32 0.49
MACD 0.13 -0.02
Stochastic Oscillator 88.96 51.88

Price Performance

Historical Comparison
EDRY
XLO

About EDRY EuroDry Ltd.

EuroDry Ltd is a holding company. It is a provider of ocean-going transportation. The company owns and operates dry bulk carriers that transport bulk such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers. It operates under one operating and one reportable segment, that of operating dry bulk vessels.

About XLO Xilio Therapeutics Inc.

Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.

Share on Social Networks: